Earnings ·
Reports Q3 net loss of $21.3M and raises $22.3M via ATM offering
TECXTectonic Therapeutic, Inc.
Tectonic Therapeutic reported a net loss of $21.3 million for the third quarter ended September 30, 2026, compared to a $19.0 million loss in the prior-year period. The company raised approximately $22.3 million in net proceeds from an at-the-market equity offering during the quarter. Cash and cash equivalents totaled $234.7 million as of September 30, 2026, providing a runway into the first quarter of 2029. Clinical updates include favorable Phase 1a safety data for TX2100, FDA Fast Track designation for HHT, dosing of the first patient in the ALPINE Phase 2a trial for TX45, and expected topline results from the APEX Phase 2 trial by January 2027. Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors.